ADVANCED ENZYME TECHNOLOGIES Financial Statement Analysis
|
||
|
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 17.09% YoY .
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 28.58 % YoY. |
||
ADVANCED ENZYME TECHNOLOGIES Last 5 Annual Financial Results
[BOM: 540025|NSE : ADVENZYMES]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹746 Cr | ₹637 Cr | ₹624 Cr | ₹541 Cr | ₹529 Cr |
| Expenses | ₹516 Cr | ₹441 Cr | ₹419 Cr | ₹383 Cr | ₹327 Cr |
| Operating Profit (Excl OI) | ₹229 Cr | ₹196 Cr | ₹205 Cr | ₹158 Cr | ₹203 Cr |
| Other Income | ₹36 Cr | ₹33 Cr | ₹37 Cr | ₹25 Cr | ₹6.42 Cr |
| Interest | ₹3.73 Cr | ₹4.63 Cr | ₹4.12 Cr | ₹3.48 Cr | ₹2.96 Cr |
| Depreciation | ₹40 Cr | ₹37 Cr | ₹35 Cr | ₹35 Cr | ₹35 Cr |
| Profit Before Tax | ₹233 Cr | ₹187 Cr | ₹188 Cr | ₹140 Cr | ₹171 Cr |
| Profit After Tax | ₹174 Cr | ₹134 Cr | ₹137 Cr | ₹104 Cr | ₹124 Cr |
| Consolidated Net Profit | ₹169 Cr | ₹131 Cr | ₹133 Cr | ₹106 Cr | ₹120 Cr |
| Earnings Per Share (Rs) | ₹15.07 | ₹11.72 | ₹11.92 | ₹9.45 | ₹10.70 |
| PAT Margin (%) | 23.24 | 21.03 | 21.92 | 19.18 | 23.34 |
| ROE(%) | 11.43 | 9.79 | 10.72 | 8.94 | 12.04 |
| ROCE(%) | 15.27 | 13.76 | 14.78 | 12.26 | 16.66 |
| Total Debt/Equity(x) | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 3,489.9 Cr |
| Revenue (TTM) | : | ₹ 745.8 Cr |
| Net Profit(TTM) | : | ₹ 173.6 Cr |
| EPS (TTM) | : | ₹ 15.5 |
| P/E (TTM) | : | 20.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ADVANCED ENZYME TECHNOLOGIES | -1% | 1.2% | -8.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.8% | 6.8% | 17.8% |
| DIVIS LABORATORIES | 6.7% | 18.5% | 12.2% |
| TORRENT PHARMACEUTICALS | -3.7% | 5.5% | 39.8% |
| CIPLA | 5.7% | 0.6% | -1.4% |
| DR REDDYS LABORATORIES | -2% | -15.8% | -8.4% |
| MANKIND PHARMA | 1.4% | 1.8% | -2% |
| LUPIN | 2.3% | 1.2% | 25.9% |
| ZYDUS LIFESCIENCES | 0.8% | 0.9% | 15% |
ADVANCED ENZYME TECHNOLOGIES Revenues
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 17.09 % |
| 5 Yr CAGR | 8.94 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹746 Cr | 17.09 | |
| Mar2025 | ₹637 Cr | 2.09 | |
| Mar2024 | ₹624 Cr | 15.39 | |
| Mar2023 | ₹541 Cr | 2.13 | |
| Mar2022 | ₹529 Cr | - | |
ADVANCED ENZYME TECHNOLOGIES Operating Profit
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 17.26 % |
| 5 Yr CAGR | 3.14 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹229 Cr | 17.26 | |
| Mar2025 | ₹196 Cr | -4.79 | |
| Mar2024 | ₹205 Cr | 30.38 | |
| Mar2023 | ₹158 Cr | -22.25 | |
| Mar2022 | ₹203 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 0.13 % |
| 5 Yr CAGR | -5.33 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 30.74% | 0.13 | |
| Mar2025 | 30.7% | -6.72 | |
| Mar2024 | 32.91% | 12.98 | |
| Mar2023 | 29.13% | -23.88 | |
| Mar2022 | 38.27% | - | |
ADVANCED ENZYME TECHNOLOGIES Profit After Tax
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 28.68 % |
| 5 Yr CAGR | 8.99 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹169 Cr | 28.68 | |
| Mar2025 | ₹131 Cr | -1.64 | |
| Mar2024 | ₹133 Cr | 26.19 | |
| Mar2023 | ₹106 Cr | -11.66 | |
| Mar2022 | ₹120 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 10.51 % |
| 5 Yr CAGR | -0.11 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 23.24 % | 10.51 | |
| Mar2025 | 21.03 % | -4.06 | |
| Mar2024 | 21.92 % | 14.29 | |
| Mar2023 | 19.18 % | -17.82 | |
| Mar2022 | 23.34 % | - | |
ADVANCED ENZYME TECHNOLOGIES Earnings Per Share (EPS)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 28.58 % |
| 5 Yr CAGR | 8.94 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹15 | 28.58 | |
| Mar2025 | ₹12 | -1.68 | |
| Mar2024 | ₹12 | 26.14 | |
| Mar2023 | ₹9.45 | -11.68 | |
| Mar2022 | ₹11 | - | |
ADVANCED ENZYME TECHNOLOGIES Return on Capital Employed (ROCE)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 10.97 % |
| 5 Yr CAGR | -2.15 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 15.27% | 10.97 | |
| Mar2025 | 13.76% | -6.90 | |
| Mar2024 | 14.78% | 20.55 | |
| Mar2023 | 12.26% | -26.41 | |
| Mar2022 | 16.66% | - | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Current Share Price | : | ₹311.6 |
| Current MarketCap | : | ₹ 3,489.9 Cr |
| Updated EOD on | : | Jul 29,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | -1% |
1.2% |
-8.5% |
| SENSEX | 1.2% |
1.2% |
-5.5% |
ADVANCED ENZYME TECHNOLOGIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2% | 3.6% | 13% |
| BSE 1000 | 0.9% | 1.6% | -0.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 0.9% | 1.5% | -0% |
| NIFTY SMALLCAP 500 | 0.5% | 1.6% | NA |
| NIFTY MICROCAP 250 | 0.2% | 0.7% | 2% |
You may also like the below Video Courses
FAQ about ADVANCED ENZYME TECHNOLOGIES Financials
How the annual revenues of ADVANCED ENZYME TECHNOLOGIES have changed ?
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 17.09% YoY .
How the Earnings per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES have changed?
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 28.58 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs